A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Clinical trial NCT02452918 · COMPLETED
Trial details
- NCT number
- NCT02452918
- Sponsor
- The Medicines Company
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-29
- Primary completion
- 2016-07-05
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.